Home » Stocks » ChemoCentryx

ChemoCentryx, Inc. (CCXI)

Stock Price: $54.30 USD -0.43 (-0.79%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $54.13 -0.17 (-0.31%) Aug 4, 4:11 PM

Stock Price Chart

Key Info

Market Cap 3.64B
Revenue (ttm) 33.81M
Net Income (ttm) -65.23M
Shares Out 67.83M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $54.30
Previous Close $54.73
Change ($) -0.43
Change (%) -0.79%
Day's Open 54.56
Day's Range 53.37 - 55.14
Day's Volume 431,477
52-Week Range 6.16 - 65.43

More Stats

Market Cap 3.64B
Enterprise Value 3.48B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.83M
Float 43.34M
EPS (basic) -1.1
EPS (diluted) -1.11
FCF / Share -1.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.28M
Short Ratio 6.50
Short % of Float 10.95%
Beta 2.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 107.69
PB Ratio 59.43
Revenue 33.81M
Operating Income -67.90M
Net Income -65.23M
Free Cash Flow -80.90M
Net Cash 159.51M
Net Cash / Share 2.38
Gross Margin -101.00%
Operating Margin -200.83%
Profit Margin -192.90%
FCF Margin -239.27%
ROA -19.35%
ROE -92.65%
ROIC -47.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$73.00*
(34.44% upside)
Low
61.0
Current: $54.30
High
95.0
Target: 73.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue36.1342.8882.5011.94--6.065.4231.6734.86
Revenue Growth-15.74%-48.03%591.22%---11.83%-82.89%-9.14%-
Gross Profit36.1342.8882.5011.94--6.065.4231.6734.86
Operating Income-58.30-40.2716.49-40.72-47.69-47.40-39.12-39.63-4.30-5.96
Net Income-55.49-37.9717.86-39.96-47.31-46.93-38.67-39.89-4.62-3.10
Shares Outstanding56.9049.8148.4146.4343.8943.2840.9235.414.214.08
Earnings Per Share-0.98-0.760.36-0.86-1.08-1.08-0.95-1.13-1.10-0.76
Operating Cash Flow-70.1216.444.8839.15-39.33-34.32-33.32-32.233.4218.64
Capital Expenditures-0.79-0.84-0.72-0.30-0.22-0.35-0.55-0.47-0.17-1.19
Free Cash Flow-70.9115.604.1638.84-39.55-34.67-33.87-32.703.2517.44
Cash & Equivalents17317712711871.2873.3613310389.4981.58
Total Debt19.7919.694.68---0.330.9011.921.28
Net Cash / Debt15315712311871.2873.3613310277.5780.29
Assets20918318915678.1611715212210298.13
Liabilities1431691101065.658.387.1111.9825.5521.36
Book Value66.0014.7479.2749.8972.5110914511076.0076.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ChemoCentryx, Inc.
Country United States
Employees 82
CEO Thomas J. Schall

Stock Information

Ticker Symbol CCXI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CCXI
IPO Date February 8, 2012

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.